Reviewing PURE Bioscience (OTCMKTS:PURE) and Rockwell Medical (NASDAQ:RMTI)

PURE Bioscience (OTCMKTS:PURE) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares PURE Bioscience and Rockwell Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PURE Bioscience	$2.20 million	4.14	-$2.40 million	($0.03)	-2.33
Rockwell Medical	$69.26 million	0.41	-$5.31 million	($0.15)	-4.79

PURE Bioscience has higher earnings, but lower revenue than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than PURE Bioscience, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

23.3% of Rockwell Medical shares are held by institutional investors. 35.6% of PURE Bioscience shares are held by company insiders. Comparatively, 1.9% of Rockwell Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares PURE Bioscience and Rockwell Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PURE Bioscience	-108.77%	N/A	-356.86%
Rockwell Medical	-7.98%	-15.41%	-9.62%

Volatility & Risk

PURE Bioscience has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for PURE Bioscience and Rockwell Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PURE Bioscience	0	0	0	0	0.00
Rockwell Medical	1	0	1	0	2.00

Rockwell Medical has a consensus price target of $2.00, suggesting a potential upside of 178.47%. Given Rockwell Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Rockwell Medical is more favorable than PURE Bioscience.

Summary

Rockwell Medical beats PURE Bioscience on 8 of the 14 factors compared between the two stocks.

About PURE Bioscience

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

About Rockwell Medical

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.